Statin therapy after acute myocardial infarction: are we adequately treating high-risk patients?
- PMID: 11822972
- DOI: 10.1007/s11883-002-0032-4
Statin therapy after acute myocardial infarction: are we adequately treating high-risk patients?
Abstract
After acute myocardial infarction, patients remain at high risk for recurrent cardiovascular events and mortality. Despite the compelling scientific and clinical trial evidence that lipid-lowering medications reduce mortality in patients after acute myocardial infarction, this life-saving therapy continues to be underutilized. A number of studies in a variety of clinical settings have documented that a significant proportion of patients after myocardial infarction are not receiving treatment with lipid-lowering medications when guided by conventional care. It has recently been demonstrated that implementation of a hospital-based system for initiation of statins prior to hospital discharge results in a marked increase in treatment rates, improved long-term patient compliance, more patients reaching low-density lipoprotein levels of less than 100 mg/dL, and improved clinical outcomes. Adopting in-hospital initiation of lipid-lowering medications as the standard of care for patients hospitalized with acute myocardial infarction could dramatically improve treatment rates and thus substantially reduce the risk of future coronary events and prolong life in the large number of patients hospitalized each year.
Similar articles
-
The role of in-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes.Rev Cardiovasc Med. 2003;4 Suppl 3:S37-46. Rev Cardiovasc Med. 2003. PMID: 14564233 Review.
-
Improving lipid evaluation and management in medicare patients hospitalized for acute myocardial infarction.Arch Intern Med. 2001 Mar 26;161(6):839-44. doi: 10.1001/archinte.161.6.839. Arch Intern Med. 2001. PMID: 11268226 Clinical Trial.
-
Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.Circulation. 2001 Jan 2;103(1):38-44. doi: 10.1161/01.cir.103.1.38. Circulation. 2001. PMID: 11136683
-
The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes.Rev Cardiovasc Med. 2002;3 Suppl 3:S2-S10. Rev Cardiovasc Med. 2002. PMID: 12447156 Review.
-
Lipid-lowering drug use and cardiovascular events after myocardial infarction.Ann Pharmacother. 2002 May;36(5):751-7. doi: 10.1345/aph.1A308. Ann Pharmacother. 2002. PMID: 11978147
Cited by
-
Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx.Br J Pharmacol. 2010 Aug;160(7):1765-72. doi: 10.1111/j.1476-5381.2010.00817.x. Br J Pharmacol. 2010. PMID: 20649578 Free PMC article.
-
Early Effects of Atorvastatin on Vitamin D and Parathyroid Hormone Serum Levels Following Acute Myocardial Infarction.J Res Pharm Pract. 2019 Jan-Mar;8(1):7-12. doi: 10.4103/jrpp.JRPP_18_55. J Res Pharm Pract. 2019. PMID: 30911557 Free PMC article.
-
Lipid-lowering therapies in the management of acute coronary syndromes.Curr Cardiol Rep. 2002 Jul;4(4):320-6. doi: 10.1007/s11886-002-0068-7. Curr Cardiol Rep. 2002. PMID: 12052271 Review.
-
Improved survival of diabetic foot ulcer patients 1995-2008: possible impact of aggressive cardiovascular risk management.Diabetes Care. 2008 Nov;31(11):2143-7. doi: 10.2337/dc08-1242. Epub 2008 Aug 12. Diabetes Care. 2008. PMID: 18697900 Free PMC article.
-
Insufficient treatment of hypercholesterolemia among patients hospitalized with chest pain.Clin Cardiol. 2006 Jun;29(6):259-62. doi: 10.1002/clc.4960290607. Clin Cardiol. 2006. PMID: 16796076 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical